Update from the 5th Conference on Retroviruses and Opportunistic Infections.
Vazquez
E
E
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000627:therapeutic use; D019888:Nelfinavir / Q000008:administration & dosage / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019258:Saquinavir / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; D019888:Nelfinavir; D019258:Saquinavir